{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:19:18Z","timestamp":1791951558980,"version":"4.3.4"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32200533"],"award-info":[{"award-number":["32200533"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20241796"],"award-info":[{"award-number":["BK20241796"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06180-4","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T08:36:06Z","timestamp":1738917366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Targeting ferroptosis in prostate cancer management: molecular mechanisms, multidisciplinary strategies and translational perspectives"],"prefix":"10.1186","volume":"23","author":[{"given":"Hubo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongming","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5016-575X","authenticated-orcid":false,"given":"Wenying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6543-0317","authenticated-orcid":false,"given":"Yuxin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"10437","key":"6180_CR1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403(10437):1683\u2013722.","journal-title":"Lancet"},{"issue":"1","key":"6180_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353.","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"6180_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"6180_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9.","journal-title":"Nat Rev Dis Primers"},{"issue":"18","key":"6180_CR5","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1101\/gad.1965810","volume":"24","author":"MM Shen","year":"2010","unstructured":"Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010;24(18):1967\u20132000.","journal-title":"Genes Dev"},{"key":"6180_CR6","doi-asserted-by":"crossref","unstructured":"Leenen RCA, Venderbos LDF, Helleman J, Gomez Rivas J, Vynckier P, Annemans L et al. Prostate Cancer Early detection in the European Union and UK. Eur Urol. 2024.","DOI":"10.1016\/j.eururo.2024.07.019"},{"issue":"2","key":"6180_CR7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.juro.2017.01.103","volume":"198","author":"MA Liss","year":"2017","unstructured":"Liss MA, Ehdaie B, Loeb S, Meng MV, Raman JD, Spears V, Stroup SP. An update of the American Urological Association White Paper on the Prevention and Treatment of the more common complications related to prostate biopsy. J Urol. 2017;198(2):329\u201334.","journal-title":"J Urol"},{"issue":"6","key":"6180_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/jnci\/djp001","volume":"101","author":"G Draisma","year":"2009","unstructured":"Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374\u201383.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"6180_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243\u201362.","journal-title":"Eur Urol"},{"issue":"9","key":"6180_CR10","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41573-023-00749-8","volume":"22","author":"K Hadian","year":"2023","unstructured":"Hadian K, Stockwell BR. The therapeutic potential of targeting regulated non-apoptotic cell death. Nat Rev Drug Discov. 2023;22(9):723\u201342.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"6180_CR11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/nrd.2015.6","volume":"15","author":"M Conrad","year":"2016","unstructured":"Conrad M, Angeli JP, Vandenabeele P, Stockwell BR. Regulated necrosis: disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 2016;15(5):348\u201366.","journal-title":"Nat Rev Drug Discov"},{"issue":"7679","key":"6180_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551(7679):247\u201350.","journal-title":"Nature"},{"issue":"7545","key":"6180_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, Baer R, Gu W. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57\u201362.","journal-title":"Nature"},{"issue":"6","key":"6180_CR14","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, Corey E, Paulmurugan R, Stoyanova T. Ferroptosis Inducers are a Novel Therapeutic Approach for Advanced prostate Cancer. Cancer Res. 2021;81(6):1583\u201394.","journal-title":"Cancer Res"},{"issue":"27","key":"6180_CR15","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/s41388-024-03057-6","volume":"43","author":"J Zhao","year":"2024","unstructured":"Zhao J, Shen J, Mao L, Yang T, Liu J, Hongbin S. Cancer associated fibroblast secreted Mir-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer. Oncogene. 2024;43(27):2104\u201314.","journal-title":"Oncogene"},{"issue":"2","key":"6180_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death Nexus linking metabolism, Redox Biology, and Disease. Cell. 2017;171(2):273\u201385.","journal-title":"Cell"},{"issue":"4","key":"6180_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"6180_CR18","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060\u201372.","journal-title":"Cell"},{"issue":"2","key":"6180_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cell.2023.11.044","volume":"187","author":"K Newton","year":"2024","unstructured":"Newton K, Strasser A, Kayagaki N, Dixit VM. Cell death. Cell. 2024;187(2):235\u201356.","journal-title":"Cell"},{"issue":"5","key":"6180_CR20","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.cell.2019.04.024","volume":"177","author":"DR Green","year":"2019","unstructured":"Green DR. The coming decade of cell death research: five riddles. Cell. 2019;177(5):1094\u2013107.","journal-title":"Cell"},{"issue":"7","key":"6180_CR21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22(7):381\u201396.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"6180_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bbrc.2019.11.110","volume":"522","author":"E Dai","year":"2020","unstructured":"Dai E, Meng L, Kang R, Wang X, Tang D. ESCRT-III-dependent membrane repair blocks ferroptosis. Biochem Biophys Res Commun. 2020;522(2):415\u201321.","journal-title":"Biochem Biophys Res Commun"},{"issue":"14","key":"6180_CR23","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"185","author":"BR Stockwell","year":"2022","unstructured":"Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185(14):2401\u201321.","journal-title":"Cell"},{"issue":"1","key":"6180_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/mc.22474","volume":"56","author":"AL Greenshields","year":"2017","unstructured":"Greenshields AL, Shepherd TG, Hoskin DW. Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate. Mol Carcinog. 2017;56(1):75\u201393.","journal-title":"Mol Carcinog"},{"issue":"6","key":"6180_CR25","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to Iron Out Cancer. Cancer Cell. 2019;35(6):830\u201349.","journal-title":"Cancer Cell"},{"issue":"4","key":"6180_CR26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","volume":"42","author":"G Lei","year":"2024","unstructured":"Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell. 2024;42(4):513\u201334.","journal-title":"Cancer Cell"},{"issue":"5","key":"6180_CR27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrc3711","volume":"14","author":"KT Bieging","year":"2014","unstructured":"Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014;14(5):359\u201370.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"6180_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13062-021-00298-3","volume":"16","author":"E Panatta","year":"2021","unstructured":"Panatta E, Zampieri C, Melino G, Amelio I. Understanding p53 tumour suppressor network. Biol Direct. 2021;16(1):14.","journal-title":"Biol Direct"},{"issue":"1","key":"6180_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/cdd.2017.171","volume":"25","author":"AM Kaiser","year":"2018","unstructured":"Kaiser AM, Attardi LD. Deconstructing networks of p53-mediated tumor suppression in vivo. Cell Death Differ. 2018;25(1):93\u2013103.","journal-title":"Cell Death Differ"},{"issue":"10","key":"6180_CR30","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41556-018-0178-0","volume":"20","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20(10):1181\u201392.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"6180_CR31","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/s41467-022-29905-1","volume":"13","author":"P Koppula","year":"2022","unstructured":"Koppula P, Lei G, Zhang Y, Yan Y, Mao C, Kondiparthi L, et al. A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers. Nat Commun. 2022;13(1):2206.","journal-title":"Nat Commun"},{"issue":"1","key":"6180_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","volume":"34","author":"M de la Rojo","year":"2018","unstructured":"de la Rojo M, Chapman E, Zhang DD. NRF2 and the hallmarks of Cancer. Cancer Cell. 2018;34(1):21\u201343.","journal-title":"Cancer Cell"},{"issue":"28","key":"6180_CR33","doi-asserted-by":"publisher","first-page":"e2122840119","DOI":"10.1073\/pnas.2122840119","volume":"119","author":"L Zhang","year":"2022","unstructured":"Zhang L, Hobeika CS, Khabibullin D, Yu D, Filippakis H, Alchoueiry M, et al. Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11. Proc Natl Acad Sci U S A. 2022;119(28):e2122840119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"6180_CR34","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1039\/D0CS00718H","volume":"50","author":"Y Xiong","year":"2021","unstructured":"Xiong Y, Xiao C, Li Z, Yang X. Engineering nanomedicine for glutathione depletion-augmented cancer therapy. Chem Soc Rev. 2021;50(10):6013\u201341.","journal-title":"Chem Soc Rev"},{"issue":"2","key":"6180_CR35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2014.11.019","volume":"27","author":"IS Harris","year":"2015","unstructured":"Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell. 2015;27(2):211\u201322.","journal-title":"Cancer Cell"},{"issue":"8","key":"6180_CR36","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12(8):599\u2013620.","journal-title":"Protein Cell"},{"issue":"12","key":"6180_CR37","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931\u201347.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"6180_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, Sun Y, Zeng F, Chen X, Deng G. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther. 2024;9(1):55.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"6180_CR39","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18(5):280\u201396.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"6180_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","volume":"20","author":"E Dai","year":"2021","unstructured":"Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer. 2021;20(1):171.","journal-title":"Mol Cancer"},{"issue":"3","key":"6180_CR41","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"key":"6180_CR42","doi-asserted-by":"crossref","unstructured":"Nakamura T, Conrad M. Exploiting ferroptosis vulnerabilities in cancer. Nat Cell Biol. 2024.","DOI":"10.1038\/s41556-024-01425-8"},{"key":"6180_CR43","doi-asserted-by":"crossref","unstructured":"Efimova I, Catanzaro E, Van der Meeren L, Turubanova VD, Hammad H, Mishchenko TA et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J Immunother Cancer. 2020;8(2).","DOI":"10.1136\/jitc-2020-001369"},{"issue":"1","key":"6180_CR44","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1038\/s41467-022-31218-2","volume":"13","author":"B Wiernicki","year":"2022","unstructured":"Wiernicki B, Maschalidi S, Pinney J, Adjemian S, Vanden Berghe T, Ravichandran KS, Vandenabeele P. Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity. Nat Commun. 2022;13(1):3676.","journal-title":"Nat Commun"},{"issue":"2","key":"6180_CR45","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/2326-6066.CIR-20-0384","volume":"9","author":"JM Drijvers","year":"2021","unstructured":"Drijvers JM, Gillis JE, Muijlwijk T, Nguyen TH, Gaudiano EF, Harris IS, et al. Pharmacologic screening identifies metabolic vulnerabilities of CD8(+) T cells. Cancer Immunol Res. 2021;9(2):184\u201399.","journal-title":"Cancer Immunol Res"},{"issue":"31","key":"6180_CR46","doi-asserted-by":"publisher","first-page":"e2007630","DOI":"10.1002\/adma.202007630","volume":"33","author":"JL Liang","year":"2021","unstructured":"Liang JL, Luo GF, Chen WH, Zhang XZ. Recent advances in Engineered materials for immunotherapy-involved Combination Cancer Therapy. Adv Mater. 2021;33(31):e2007630.","journal-title":"Adv Mater"},{"issue":"1","key":"6180_CR47","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","volume":"28","author":"T Powles","year":"2022","unstructured":"Powles T, Yuen KC, Gillessen S, Kadel EE 3rd, Rathkopf D, Matsubara N, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022;28(1):144\u201353.","journal-title":"Nat Med"},{"issue":"81","key":"6180_CR48","doi-asserted-by":"publisher","first-page":"eade4656","DOI":"10.1126\/sciimmunol.ade4656","volume":"8","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Zhao Y, Wen J, Liu S, Huang T, Hatial I, et al. Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Sci Immunol. 2023;8(81):eade4656.","journal-title":"Sci Immunol"},{"issue":"1","key":"6180_CR49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41419-024-06464-5","volume":"15","author":"Y Gu","year":"2024","unstructured":"Gu Y, Wu S, Fan J, Meng Z, Gao G, Liu T, Wang Q, Xia H, Wang X, Wu K. CYLD regulates cell ferroptosis through Hippo\/YAP signaling in prostate cancer progression. Cell Death Dis. 2024;15(1):79.","journal-title":"Cell Death Dis"},{"issue":"9\u201310","key":"6180_CR50","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s10495-024-01941-w","volume":"29","author":"A Fan","year":"2024","unstructured":"Fan A, Li Y, Zhang Y, Meng W, Pan W, Chen M, Ma Z, Chen W. Loss of AR-regulated AFF3 contributes to prostate cancer progression and reduces ferroptosis sensitivity by downregulating ACSL4 based on single-cell sequencing analysis. Apoptosis. 2024;29(9\u201310):1679\u201395.","journal-title":"Apoptosis"},{"issue":"2","key":"6180_CR51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3892\/ol.2022.13186","volume":"23","author":"P Xu","year":"2022","unstructured":"Xu P, Wang Y, Deng Z, Tan Z, Pei X. MicroRNA-15a promotes prostate cancer cell ferroptosis by inhibiting GPX4 expression. Oncol Lett. 2022;23(2):67.","journal-title":"Oncol Lett"},{"issue":"2","key":"6180_CR52","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/biof.1927","volume":"49","author":"W Xu","year":"2023","unstructured":"Xu W, Ding J, Li B, Sun T, You X, He Q, Sheng W. Effects of icariin and curcumol on autophagy, ferroptosis, and lipid metabolism based on miR-7\/m-TOR\/SREBP1 pathway on prostate cancer. BioFactors. 2023;49(2):438\u201356.","journal-title":"BioFactors"},{"key":"6180_CR53","doi-asserted-by":"publisher","first-page":"176007","DOI":"10.1016\/j.ejphar.2023.176007","volume":"957","author":"Y Yu","year":"2023","unstructured":"Yu Y, Huang X, Liang C, Zhang P. Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer. Eur J Pharmacol. 2023;957:176007.","journal-title":"Eur J Pharmacol"},{"issue":"19","key":"6180_CR54","doi-asserted-by":"publisher","first-page":"23096","DOI":"10.18632\/aging.203602","volume":"13","author":"H Cao","year":"2021","unstructured":"Cao H, Wang D, Sun P, Chen L, Feng Y, Gao R. Zhoushi Qi Ling decoction represses docetaxel resistance and glycolysis of castration-resistant prostate cancer via regulation of SNHG10\/miR-1271-5p\/TRIM66 axis. Aging. 2021;13(19):23096\u2013107.","journal-title":"Aging"},{"issue":"12","key":"6180_CR55","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.7150\/jca.84363","volume":"14","author":"H Cao","year":"2023","unstructured":"Cao H, Wu X, Gao R, Chen L, Feng Y, Wang D. QiLing Decoction promotes ferroptosis of castration-resistant prostate cancer cells by inhibiting FSP1 in vitro and in vivo. J Cancer. 2023;14(12):2236\u201345.","journal-title":"J Cancer"},{"key":"6180_CR56","doi-asserted-by":"publisher","first-page":"789284","DOI":"10.3389\/fonc.2022.789284","volume":"12","author":"O Vakhrusheva","year":"2022","unstructured":"Vakhrusheva O, Erb HHH, Braunig V, Markowitsch SD, Schupp P, Baer PC, et al. Artesunate inhibits the growth behavior of Docetaxel-resistant prostate Cancer cells. Front Oncol. 2022;12:789284.","journal-title":"Front Oncol"},{"issue":"12","key":"6180_CR57","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.7150\/ijbs.101039","volume":"20","author":"B Li","year":"2024","unstructured":"Li B, Cheng B, Huang H, Huang S, Yu S, Li Z, Peng S, Du T, Xie R, Huang H. Darolutamide-mediated phospholipid remodeling induces ferroptosis through the SREBP1-FASN axis in prostate cancer. Int J Biol Sci. 2024;20(12):4635\u201353.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"6180_CR58","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41420-024-02152-7","volume":"10","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Liu C, Yang Y, Ren H, Ren T, Huang Y, Zhang S, Sun Q, Huang H. TRIB3 inhibition by palbociclib sensitizes prostate cancer to ferroptosis via downregulating SOX2\/SLC7A11 expression. Cell Death Discov. 2024;10(1):425.","journal-title":"Cell Death Discov"},{"key":"6180_CR59","doi-asserted-by":"publisher","first-page":"1110146","DOI":"10.3389\/fphar.2023.1110146","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Xie T, Zhang S, Yin H, Zhang X, Zhang S, et al. Second generation androgen receptor antagonist, TQB3720 abrogates prostate cancer growth via AR\/GPX4 axis activated ferroptosis. Front Pharmacol. 2023;14:1110146.","journal-title":"Front Pharmacol"},{"key":"6180_CR60","doi-asserted-by":"publisher","first-page":"105305","DOI":"10.1016\/j.phrs.2020.105305","volume":"164","author":"X Zhou","year":"2021","unstructured":"Zhou X, Zou L, Chen W, Yang T, Luo J, Wu K, et al. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer. Pharmacol Res. 2021;164:105305.","journal-title":"Pharmacol Res"},{"issue":"1","key":"6180_CR61","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41420-023-01383-4","volume":"9","author":"F Maccarinelli","year":"2023","unstructured":"Maccarinelli F, Coltrini D, Mussi S, Bugatti M, Turati M, Chiodelli P, et al. Iron supplementation enhances RSL3-induced ferroptosis to treat naive and prevent castration-resistant prostate cancer. Cell Death Discov. 2023;9(1):81.","journal-title":"Cell Death Discov"},{"issue":"1","key":"6180_CR62","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13020-024-00881-6","volume":"19","author":"S Liu","year":"2024","unstructured":"Liu S, Tao Y, Wu S, Lin J, Fu S, Lu J, et al. Sanguinarine chloride induces ferroptosis by regulating ROS\/BACH1\/HMOX1 signaling pathway in prostate cancer. Chin Med. 2024;19(1):7.","journal-title":"Chin Med"},{"issue":"1","key":"6180_CR63","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/pros.24626","volume":"84","author":"P Zou","year":"2024","unstructured":"Zou P, Chen Z, He Q, Zhuo Y. Polyphyllin I induces ferroptosis in castration-resistant prostate cancer cells through the ERK\/DNMT1\/ACSL4 axis. Prostate. 2024;84(1):64\u201373.","journal-title":"Prostate"},{"issue":"2","key":"6180_CR64","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1248\/bpb.b23-00544","volume":"47","author":"B Sun","year":"2024","unstructured":"Sun B, Zhang L, Wu B, Luo X. A Morpholine Derivative N-(4-Morpholinomethylene)ethanesulfonamide induces ferroptosis in Tumor cells by targeting NRF2. Biol Pharm Bull. 2024;47(2):417\u201326.","journal-title":"Biol Pharm Bull"},{"key":"6180_CR65","doi-asserted-by":"publisher","first-page":"102751","DOI":"10.1016\/j.redox.2023.102751","volume":"63","author":"YY Cao","year":"2023","unstructured":"Cao YY, Chen YY, Wang MS, Tong JJ, Xu M, Zhao C, et al. A catalase inhibitor: targeting the NADPH-binding site for castration-resistant prostate cancer therapy. Redox Biol. 2023;63:102751.","journal-title":"Redox Biol"},{"issue":"8","key":"6180_CR66","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1007\/s00394-022-02940-w","volume":"61","author":"K Shan","year":"2022","unstructured":"Shan K, Feng N, Zhu D, Qu H, Fu G, Li J, Cui J, Chen H, Wang R, Qi Y, Chen YQ. Free docosahexaenoic acid promotes ferroptotic cell death via lipoxygenase dependent and independent pathways in cancer cells. Eur J Nutr. 2022;61(8):4059\u201375.","journal-title":"Eur J Nutr"},{"issue":"2","key":"6180_CR67","doi-asserted-by":"publisher","first-page":"59","DOI":"10.14712\/fb2022068020059","volume":"68","author":"ZC Shao","year":"2022","unstructured":"Shao ZC, Zhu BH, Huang AF, Su MQ, An LJ, Wu ZP, Jiang YJ, Guo H, Han XQ, Liu CM. Docosahexaenoic acid reverses epithelial-mesenchymal transition and drug resistance by impairing the PI3K\/AKT\/ Nrf2\/GPX4 signalling pathway in Docetaxel-resistant PC3 prostate Cancer cells. Folia Biol (Praha). 2022;68(2):59\u201371.","journal-title":"Folia Biol (Praha)"},{"issue":"23","key":"6180_CR68","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1158\/0008-5472.CAN-20-3607","volume":"81","author":"R Kumar","year":"2021","unstructured":"Kumar R, Mendonca J, Owoyemi O, Boyapati K, Thomas N, Kanacharoen S, et al. Supraphysiologic testosterone induces ferroptosis and activates Immune pathways through Nucleophagy in prostate Cancer. Cancer Res. 2021;81(23):5948\u201362.","journal-title":"Cancer Res"},{"issue":"14","key":"6180_CR69","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1158\/0008-5472.CAN-23-1489","volume":"84","author":"RK Shrestha","year":"2024","unstructured":"Shrestha RK, Nassar ZD, Hanson AR, Iggo R, Townley SL, Dehairs J, et al. ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate Cancer growth and constrain ferroptosis. Cancer Res. 2024;84(14):2313\u201332.","journal-title":"Cancer Res"},{"key":"6180_CR70","doi-asserted-by":"publisher","first-page":"103392","DOI":"10.1016\/j.redox.2024.103392","volume":"77","author":"W Lai","year":"2024","unstructured":"Lai W, Zhu W, Wu J, Huang J, Li X, Luo Y, Wang Y, Zeng H, Li M, Qiu X, Wen X. HJURP inhibits sensitivity to ferroptosis inducers in prostate cancer cells by enhancing the peroxidase activity of PRDX1. Redox Biol. 2024;77:103392.","journal-title":"Redox Biol"},{"key":"6180_CR71","doi-asserted-by":"crossref","unstructured":"Nassar ZD, Mah CY, Dehairs J, Burvenich IJ, Irani S, Centenera MM et al. Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. Elife. 2020;9.","DOI":"10.7554\/eLife.54166"},{"issue":"1","key":"6180_CR72","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1038\/s41467-020-16126-7","volume":"11","author":"A Blomme","year":"2020","unstructured":"Blomme A, Ford CA, Mui E, Patel R, Ntala C, Jamieson LE, et al. 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer. Nat Commun. 2020;11(1):2508.","journal-title":"Nat Commun"},{"key":"6180_CR73","doi-asserted-by":"publisher","first-page":"117472","DOI":"10.1016\/j.biopha.2024.117472","volume":"180","author":"J Lu","year":"2024","unstructured":"Lu J, Zou Q, Li Y, Xiong C, Tao L, Wu J, et al. FTH1P8 induces and transmits docetaxel resistance by inhibiting ferroptosis in prostate cancer. Biomed Pharmacother. 2024;180:117472.","journal-title":"Biomed Pharmacother"},{"key":"6180_CR74","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.freeradbiomed.2023.06.006","volume":"205","author":"J Nie","year":"2023","unstructured":"Nie J, Zhang P, Liang C, Yu Y, Wang X. ASCL1-mediated ferroptosis resistance enhances the progress of castration-resistant prostate cancer to neurosecretory prostate cancer. Free Radic Biol Med. 2023;205:318\u201331.","journal-title":"Free Radic Biol Med"},{"key":"6180_CR75","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.2147\/OTT.S249752","volume":"13","author":"D Liao","year":"2020","unstructured":"Liao D, Yang G, Yang Y, Tang X, Huang H, Shao J, Pan Q. Identification of pannexin 2 as a novel marker correlating with ferroptosis and malignant phenotypes of prostate Cancer cells. Onco Targets Ther. 2020;13:4411\u201321.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"6180_CR76","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/pros.24308","volume":"82","author":"R Zhao","year":"2022","unstructured":"Zhao R, Lv Y, Feng T, Zhang R, Ge L, Pan J, Han B, Song G, Wang L. ATF6alpha promotes prostate cancer progression by enhancing PLA2G4A-mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis. Prostate. 2022;82(5):617\u201329.","journal-title":"Prostate"},{"issue":"9","key":"6180_CR77","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1007\/s11010-023-04847-4","volume":"479","author":"X Fu","year":"2024","unstructured":"Fu X, Wu H, Li C, Deng G, Chen C. YAP1 inhibits RSL3-induced castration-resistant prostate cancer cell ferroptosis by driving glutamine uptake and metabolism to GSH. Mol Cell Biochem. 2024;479(9):2415\u201327.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"6180_CR78","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12672-023-00715-1","volume":"14","author":"G Jia","year":"2023","unstructured":"Jia G, Wu W, Chen L, Yu Y, Tang Q, Liu H, Jiang Q, Han B. HSF1 is a novel prognostic biomarker in high-risk prostate cancer that correlates with ferroptosis. Discov Oncol. 2023;14(1):107.","journal-title":"Discov Oncol"},{"issue":"8","key":"6180_CR79","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.7150\/jca.92379","volume":"15","author":"C Zhang","year":"2024","unstructured":"Zhang C, Yu H, Bai X, Zhou X, Feng Z, Li Y, et al. MiR-15b-3p weakens bicalutamide sensitivity in prostate cancer via targeting KLF2 to suppress ferroptosis. J Cancer. 2024;15(8):2306\u201317.","journal-title":"J Cancer"},{"key":"6180_CR80","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bbrc.2023.02.030","volume":"652","author":"G Yang","year":"2023","unstructured":"Yang G, Pan Q, Lu Y, Zhu J, Gou X. miR-29a-5p modulates ferroptosis by targeting ferritin heavy chain FTH1 in prostate cancer. Biochem Biophys Res Commun. 2023;652:6\u201313.","journal-title":"Biochem Biophys Res Commun"},{"key":"6180_CR81","doi-asserted-by":"publisher","first-page":"112376","DOI":"10.1016\/j.ecoenv.2021.112376","volume":"220","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Guo S, Wang S, Li X, Hou D, Li H, Wang L, Xu Y, Ma B, Wang H, Jiang X. LncRNA OIP5-AS1 inhibits ferroptosis in prostate cancer with long-term cadmium exposure through miR-128-3p\/SLC7A11 signaling. Ecotoxicol Environ Saf. 2021;220:112376.","journal-title":"Ecotoxicol Environ Saf"},{"key":"6180_CR82","doi-asserted-by":"publisher","first-page":"862015","DOI":"10.3389\/fonc.2022.862015","volume":"12","author":"X Jiang","year":"2022","unstructured":"Jiang X, Guo S, Xu M, Ma B, Liu R, Xu Y, Zhang Y. TFAP2C-Mediated lncRNA PCAT1 inhibits ferroptosis in Docetaxel-resistant prostate Cancer through c-Myc\/miR-25-3p\/SLC7A11 signaling. Front Oncol. 2022;12:862015.","journal-title":"Front Oncol"},{"key":"6180_CR83","doi-asserted-by":"crossref","unstructured":"Jiang H, Zhang H, Jiang S. CircDUSP22 attenuates the ferroptosis of prostate Cancer cells via miR-18a-5p\/SLC7A11\/GPX4 signaling. Comb Chem High Throughput Screen. 2024.","DOI":"10.2174\/0113862073324077240624094140"},{"issue":"3","key":"6180_CR84","doi-asserted-by":"publisher","first-page":"e2303894","DOI":"10.1002\/advs.202303894","volume":"11","author":"H Xiao","year":"2024","unstructured":"Xiao H, Du X, Tao Z, Jing N, Bao S, Gao WQ, Dong B, Fang YX. Taurine inhibits ferroptosis mediated by the crosstalk between Tumor cells and Tumor-Associated macrophages in prostate Cancer. Adv Sci (Weinh). 2024;11(3):e2303894.","journal-title":"Adv Sci (Weinh)"},{"key":"6180_CR85","doi-asserted-by":"publisher","first-page":"139716","DOI":"10.1016\/j.chemosphere.2023.139716","volume":"339","author":"J Shi","year":"2023","unstructured":"Shi J, Ma C, Zheng Z, Zhang T, Li Z, Sun X, He Z, Zhang Z, Zhang C. Low-dose antimony exposure promotes prostate cancer proliferation by inhibiting ferroptosis via activation of the Nrf2-SLC7A11-GPX4 pathway. Chemosphere. 2023;339:139716.","journal-title":"Chemosphere"},{"issue":"2","key":"6180_CR86","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/tox.23997","volume":"39","author":"B Cheng","year":"2024","unstructured":"Cheng B, Lai Y, Huang H, Peng S, Tang C, Chen J, Luo T, Wu J, He H, Wang Q, Huang H. MT1G, an emerging ferroptosis-related gene: a novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer. Environ Toxicol. 2024;39(2):927\u201341.","journal-title":"Environ Toxicol"},{"issue":"1","key":"6180_CR87","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s40001-023-01215-2","volume":"28","author":"D Feng","year":"2023","unstructured":"Feng D, Li L, Li D, Wu R, Zhu W, Wang J, Ye L, Han P. Prolyl 4-hydroxylase subunit beta (P4HB) could serve as a prognostic and radiosensitivity biomarker for prostate cancer patients. Eur J Med Res. 2023;28(1):245.","journal-title":"Eur J Med Res"},{"issue":"1","key":"6180_CR88","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1186\/s12885-022-09876-8","volume":"22","author":"C Liu","year":"2022","unstructured":"Liu C, Gao Y, Ni J, Chen S, Hu Q, Wang C, Hu M, Chen M. The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer. BMC Cancer. 2022;22(1):788.","journal-title":"BMC Cancer"},{"issue":"1","key":"6180_CR89","doi-asserted-by":"publisher","first-page":"22804","DOI":"10.1038\/s41598-023-50205-1","volume":"13","author":"J Chen","year":"2023","unstructured":"Chen J, Zhang L, Luo Y, Tan C, Hu H, Jiang Y, Xi N, Zeng Q, Peng H. Development of a ferroptosis-based molecular markers for predicting RFS in prostate cancer patients. Sci Rep. 2023;13(1):22804.","journal-title":"Sci Rep"},{"key":"6180_CR90","doi-asserted-by":"publisher","first-page":"666025","DOI":"10.3389\/fcell.2021.666025","volume":"9","author":"Z Lv","year":"2021","unstructured":"Lv Z, Wang J, Wang X, Mo M, Tang G, Xu H, Wang J, Li Y, Liu M. Identifying a ferroptosis-related gene signature for Predicting biochemical recurrence of prostate Cancer. Front Cell Dev Biol. 2021;9:666025.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"6180_CR91","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.gpb.2017.01.001","volume":"15","author":"Y Wang","year":"2017","unstructured":"Wang Y, Song F, Zhu J, Zhang S, Yang Y, Chen T, et al. GSA: genome sequence archive\u2009<\u2009sup\/>. Genomics Proteom Bioinf. 2017;15(1):14\u20138.","journal-title":"Genomics Proteom Bioinf"},{"issue":"1","key":"6180_CR92","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar R, Domrachev M, Lash AE. Gene expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207\u201310.","journal-title":"Nucleic Acids Res"},{"issue":"1A","key":"6180_CR93","first-page":"A68","volume":"19","author":"K Tomczak","year":"2015","unstructured":"Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68\u201377.","journal-title":"Contemp Oncol (Pozn)"},{"issue":"D1","key":"6180_CR94","doi-asserted-by":"publisher","first-page":"D571","DOI":"10.1093\/nar\/gkac935","volume":"51","author":"N Zhou","year":"2023","unstructured":"Zhou N, Yuan X, Du Q, Zhang Z, Shi X, Bao J, Ning Y, Peng L. FerrDb V2: update of the manually curated database of ferroptosis regulators and ferroptosis-disease associations. Nucleic Acids Res. 2023;51(D1):D571\u201382.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"6180_CR95","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.gpb.2022.09.004","volume":"21","author":"S Zhou","year":"2023","unstructured":"Zhou S, Huang Y, Xing J, Zhou X, Chen S, Chen J, Wang L, Jiang W. ncFO: a Comprehensive Resource of Curated and predicted ncRNAs Associated with Ferroptosis. Genomics Proteom Bioinf. 2023;21(2):278\u201382.","journal-title":"Genomics Proteom Bioinf"},{"issue":"4","key":"6180_CR96","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kramer","year":"2014","unstructured":"Kramer A, Green J, Pollard J Jr., Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014;30(4):523\u201330.","journal-title":"Bioinformatics"},{"issue":"D1","key":"6180_CR97","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353\u201361.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"6180_CR98","doi-asserted-by":"publisher","first-page":"D862","DOI":"10.1093\/nar\/gkr967","volume":"40","author":"MJ Cowley","year":"2012","unstructured":"Cowley MJ, Pinese M, Kassahn KS, Waddell N, Pearson JV, Grimmond SM, Biankin AV, Hautaniemi S, Wu J. PINA v2.0: mining interactome modules. Nucleic Acids Res. 2012;40(Database issue):D862\u2013865.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"6180_CR99","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638\u201346.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"6180_CR100","doi-asserted-by":"publisher","first-page":"D92","DOI":"10.1093\/nar\/gkt1248","volume":"42","author":"JH Li","year":"2014","unstructured":"Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(Database issue):D92\u201397.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"6180_CR101","doi-asserted-by":"publisher","first-page":"D239","DOI":"10.1093\/nar\/gkv1258","volume":"44","author":"CH Chou","year":"2016","unstructured":"Chou CH, Chang NW, Shrestha S, Hsu SD, Lin YL, Lee WH, et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res. 2016;44(D1):D239\u2013247.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"6180_CR102","doi-asserted-by":"publisher","first-page":"D153","DOI":"10.1093\/nar\/gku1215","volume":"43","author":"IS Vlachos","year":"2015","unstructured":"Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, Kanellos I, et al. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucleic Acids Res. 2015;43(Database issue):D153\u2013159.","journal-title":"Nucleic Acids Res"},{"key":"6180_CR103","doi-asserted-by":"publisher","first-page":"623313","DOI":"10.3389\/fonc.2021.623313","volume":"11","author":"H Liu","year":"2021","unstructured":"Liu H, Gao L, Xie T, Li J, Zhai TS, Xu Y. Identification and validation of a Prognostic signature for prostate Cancer based on ferroptosis-related genes. Front Oncol. 2021;11:623313.","journal-title":"Front Oncol"},{"key":"6180_CR104","doi-asserted-by":"publisher","first-page":"803766","DOI":"10.3389\/fcell.2022.803766","volume":"10","author":"D Feng","year":"2022","unstructured":"Feng D, Shi X, Xiong Q, Zhang F, Li D, Wei W, Yang L. A ferroptosis-related gene Prognostic Index Associated with biochemical recurrence and Radiation Resistance for patients with prostate Cancer undergoing Radical Radiotherapy. Front Cell Dev Biol. 2022;10:803766.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"6180_CR105","doi-asserted-by":"publisher","first-page":"pbad001","DOI":"10.1093\/pcmedi\/pbad001","volume":"6","author":"T Guo","year":"2023","unstructured":"Guo T, Yuan Z, Wang T, Zhang J, Tang H, Zhang N, Wang X, Chen S. Integrative analysis of ferroptosis regulators for clinical prognosis based on deep learning and potential chemotherapy sensitivity of prostate cancer. Precis Clin Med. 2023;6(1):pbad001.","journal-title":"Precis Clin Med"},{"issue":"1","key":"6180_CR106","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1038\/s41467-021-23774-w","volume":"12","author":"T Wang","year":"2021","unstructured":"Wang T, Shao W, Huang Z, Tang H, Zhang J, Ding Z, Huang K. MOGONET integrates multi-omics data using graph convolutional networks allowing patient classification and biomarker identification. Nat Commun. 2021;12(1):3445.","journal-title":"Nat Commun"},{"issue":"12","key":"6180_CR107","doi-asserted-by":"publisher","first-page":"12380","DOI":"10.1021\/acsnano.8b06399","volume":"12","author":"S Wang","year":"2018","unstructured":"Wang S, Li F, Qiao R, Hu X, Liao H, Chen L, et al. Arginine-Rich Manganese Silicate Nanobubbles as a ferroptosis-inducing Agent for Tumor-targeted Theranostics. ACS Nano. 2018;12(12):12380\u201392.","journal-title":"ACS Nano"},{"issue":"1","key":"6180_CR108","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1021\/acsnano.8b05602","volume":"13","author":"W Bao","year":"2019","unstructured":"Bao W, Liu X, Lv Y, Lu GH, Li F, Zhang F, Liu B, Li D, Wei W, Li Y. Nanolongan with multiple On-Demand conversions for ferroptosis-apoptosis combined Anticancer Therapy. ACS Nano. 2019;13(1):260\u201373.","journal-title":"ACS Nano"},{"issue":"1","key":"6180_CR109","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-021-01096-0","volume":"14","author":"Z Cheng","year":"2021","unstructured":"Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol. 2021;14(1):85.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6180_CR110","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"C Zhang","year":"2022","unstructured":"Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21(1):47.","journal-title":"Mol Cancer"},{"issue":"13","key":"6180_CR111","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.1039\/D2CS00840H","volume":"52","author":"J Shin","year":"2023","unstructured":"Shin J, Kang N, Kim B, Hong H, Yu L, Kim J, Kang H, Kim JS. One-dimensional nanomaterials for cancer therapy and diagnosis. Chem Soc Rev. 2023;52(13):4488\u2013514.","journal-title":"Chem Soc Rev"},{"issue":"6","key":"6180_CR112","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1021\/acs.biomac.4c00260","volume":"25","author":"H Zhang","year":"2024","unstructured":"Zhang H, Xing C, Yan B, Lei H, Guan Y, Zhang S, Kang Y, Pang J. Paclitaxel Overload Supramolecular oxidative stress nanoamplifier with a CDK12 inhibitor for enhanced Cancer Therapy. Biomacromolecules. 2024;25(6):3685\u2013702.","journal-title":"Biomacromolecules"},{"key":"6180_CR113","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jconrel.2021.03.007","volume":"332","author":"H Xiong","year":"2021","unstructured":"Xiong H, Wang C, Wang Z, Lu H, Yao J. Self-assembled nano-activator constructed ferroptosis-immunotherapy through hijacking endogenous iron to intracellular positive feedback loop. J Control Release. 2021;332:539\u201352.","journal-title":"J Control Release"},{"key":"6180_CR114","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jconrel.2019.03.031","volume":"302","author":"YL Liu","year":"2019","unstructured":"Liu YL, Chen D, Shang P, Yin DC. A review of magnet systems for targeted drug delivery. J Control Release. 2019;302:90\u2013104.","journal-title":"J Control Release"},{"issue":"22","key":"6180_CR115","doi-asserted-by":"publisher","first-page":"e2207077","DOI":"10.1002\/smll.202207077","volume":"19","author":"H Wang","year":"2023","unstructured":"Wang H, Guan Y, Li C, Chen J, Yue S, Qian J, et al. PEGylated manganese-zinc Ferrite nanocrystals combined with Intratumoral Implantation of micromagnets enabled synergetic prostate Cancer Therapy via Ferroptotic and Immunogenic Cell Death. Small. 2023;19(22):e2207077.","journal-title":"Small"},{"key":"6180_CR116","doi-asserted-by":"crossref","unstructured":"Li Y, Li H, Zhang K, Xu C, Wang J, Li Z et al. Genetically Engineered membrane-coated nanoparticles for enhanced prostate-specific membrane Antigen Targeting and Ferroptosis Treatment of Castration-resistant prostate Cancer. Adv Sci (Weinh). 2024:e2401095.","DOI":"10.1002\/advs.202401095"},{"issue":"10","key":"6180_CR117","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.7150\/thno.20118","volume":"7","author":"Y Zhai","year":"2017","unstructured":"Zhai Y, Su J, Ran W, Zhang P, Yin Q, Zhang Z, Yu H, Li Y. Preparation and Application of Cell membrane-camouflaged nanoparticles for Cancer Therapy. Theranostics. 2017;7(10):2575\u201392.","journal-title":"Theranostics"},{"key":"6180_CR118","doi-asserted-by":"publisher","first-page":"100484","DOI":"10.1016\/j.mtbio.2022.100484","volume":"17","author":"J Chen","year":"2022","unstructured":"Chen J, Wang Y, Han L, Wang R, Gong C, Yang G, Li Z, Gao S, Yuan Y. A ferroptosis-inducing biomimetic nanocomposite for the treatment of drug-resistant prostate cancer. Mater Today Bio. 2022;17:100484.","journal-title":"Mater Today Bio"},{"issue":"4","key":"6180_CR119","doi-asserted-by":"publisher","first-page":"7179","DOI":"10.1021\/acsnano.1c00380","volume":"15","author":"S Xie","year":"2021","unstructured":"Xie S, Sun W, Zhang C, Dong B, Yang J, Hou M, Xiong L, Cai B, Liu X, Xue W. Metabolic control by heat stress determining cell fate to ferroptosis for Effective Cancer Therapy. ACS Nano. 2021;15(4):7179\u201394.","journal-title":"ACS Nano"},{"issue":"1","key":"6180_CR120","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12951-022-01635-y","volume":"20","author":"KS Kim","year":"2022","unstructured":"Kim KS, Choi B, Choi H, Ko MJ, Kim DH, Kim DH. Enhanced natural killer cell anti-tumor activity with nanoparticles mediated ferroptosis and potential therapeutic application in prostate cancer. J Nanobiotechnol. 2022;20(1):428.","journal-title":"J Nanobiotechnol"},{"issue":"2","key":"6180_CR121","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1039\/D3NA00877K","volume":"6","author":"Y Hong","year":"2024","unstructured":"Hong Y, Hou W, Ou D, Lin M, Luo M, Wei Q. Liposome-coated nanoparticle triggers prostate cancer ferroptosis through synergetic chemodynamic-gas therapy. Nanoscale Adv. 2024;6(2):524\u201333.","journal-title":"Nanoscale Adv"},{"issue":"21","key":"6180_CR122","doi-asserted-by":"publisher","first-page":"e2311733","DOI":"10.1002\/adma.202311733","volume":"36","author":"H Wang","year":"2024","unstructured":"Wang H, Jiao D, Feng D, Liu Q, Huang Y, Hou J, Ding D, Zhang W. Transformable Supramolecular Self-assembled peptides for Cascade Self-enhanced ferroptosis primed Cancer Immunotherapy. Adv Mater. 2024;36(21):e2311733.","journal-title":"Adv Mater"},{"issue":"8","key":"6180_CR123","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1039\/D0MH01992E","volume":"8","author":"H Wang","year":"2021","unstructured":"Wang H, Zhang L, Miao Z, Zhang M, Liu H, He Q, et al. PSMA-targeted arsenic nanosheets: a platform for prostate cancer therapy via ferroptosis and ATM deficiency-triggered chemosensitization. Mater Horiz. 2021;8(8):2216\u201329.","journal-title":"Mater Horiz"},{"issue":"1","key":"6180_CR124","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41569-022-00735-4","volume":"20","author":"X Fang","year":"2023","unstructured":"Fang X, Ardehali H, Min J, Wang F. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat Rev Cardiol. 2023;20(1):7\u201323.","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"6180_CR125","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/cac2.12321","volume":"42","author":"L Wu","year":"2022","unstructured":"Wu L, Liu F, Yin L, Wang F, Shi H, Zhao Q, Yang F, Chen D, Dong X, Gu Y, Xing N. The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death. Cancer Commun (Lond). 2022;42(8):768\u201383.","journal-title":"Cancer Commun (Lond)"},{"issue":"33","key":"6180_CR126","doi-asserted-by":"publisher","first-page":"e2401095","DOI":"10.1002\/advs.202401095","volume":"11","author":"Y Li","year":"2024","unstructured":"Li Y, Li H, Zhang K, Xu C, Wang J, Li Z, et al. Genetically Engineered membrane-coated nanoparticles for enhanced prostate-specific membrane Antigen Targeting and Ferroptosis Treatment of Castration-resistant prostate Cancer. Adv Sci (Weinh). 2024;11(33):e2401095.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"6180_CR127","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-020-00946-7","volume":"13","author":"R Tang","year":"2020","unstructured":"Tang R, Xu J, Zhang B, Liu J, Liang C, Hua J, Meng Q, Yu X, Shi S. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020;13(1):110.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6180_CR128","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","volume":"7","author":"W Gao","year":"2022","unstructured":"Gao W, Wang X, Zhou Y, Wang X, Yu Y. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduct Target Ther. 2022;7(1):196.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"6180_CR129","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41419-019-1883-8","volume":"10","author":"X Xia","year":"2019","unstructured":"Xia X, Wang X, Cheng Z, Qin W, Lei L, Jiang J, Hu J. The role of pyroptosis in cancer: pro-cancer or pro-host? Cell Death Dis. 2019;10(9):650.","journal-title":"Cell Death Dis"},{"key":"6180_CR130","doi-asserted-by":"publisher","first-page":"789004","DOI":"10.3389\/fcell.2021.789004","volume":"9","author":"Z Nie","year":"2021","unstructured":"Nie Z, Chen M, Gao Y, Huang D, Cao H, Peng Y, Guo N, Zhang S. Regulated cell death in urinary malignancies. Front Cell Dev Biol. 2021;9:789004.","journal-title":"Front Cell Dev Biol"},{"key":"6180_CR131","doi-asserted-by":"crossref","unstructured":"Yang Y, Liu T, Hu C, Xia H, Liu W, Chen J, Wu S, Jiang Y, Xu Y, Liu W, Zhao L. Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castration\u2013resistant prostate cancer. Oncol Rep. 2021;45(4).","DOI":"10.3892\/or.2021.7976"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06180-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06180-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06180-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T08:36:14Z","timestamp":1738917374000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06180-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":131,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6180"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06180-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}